Aytu Bioscience
AYTUAytu Bioscience in brief
Aytu Bioscience is a listed company in the Biotechnology industry, based in Denver, Colorado, USA. Its market value was $21 M on 26 October 2026, which makes it the 24,234th largest listed company in the world and the 4,150th largest in the USA on this site. In the year to June 2026 it had sales of $58 M and a net loss of $14 M. Joshua R. Disbrow is its chief executive. Its largest product and service lines by sales in 2026 were ADHD Portfolio (80%), E X X U A Portfolio (11%) and The Pediatric Portfolio (9%). Its shares trade under the symbol AYTU (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Aytu Bioscience timeline
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- ✎Renamed Aytu Bioscience, IncFormerly Rosewind CORP.
- 2021
- ✎Renamed Aytu Biopharma, IncFormerly Aytu Bioscience, Inc.
- 2023
- 💰Record revenue of $107 millionFY2023, the highest of the 9 years on record.
Events of Aytu Bioscience from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,451 (Jan 2020) · #3,671 (Jan 2021) · #5,036 (Jan 2022) · #5,509 (Dec 2022) · #5,421 (Jul 2023) · #4,412 (Jan 2024) · #2,266 (Mar 2026) · #3,891 (Aug 2026) · #4,101 (Oct 2026) · #4,153 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.4×
- Price / book
- 0.6×
- Free cash flow yield
- 15.7%
- Net margin (TTM)
- -24.8%
- Operating margin
- -14.5%
- Return on equity
- -40.4%
- Liabilities / assets
- 66.4%
- Net debt
- $-17M
- Revenue growth
- -13.3%
- R&D / revenue
- 0.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $58M | -13.3% | $-8M | $-14M | -24.8% |
| Jun 2025 | $66M | +1.8% | $-8M | $-14M | -20.4% |
| Jun 2024 | $65M | -39.3% | $-2M | $-16M | -24.3% |
| Jun 2023 | $107M | +11.1% | $-17M | $-17M | -15.9% |
| Jun 2022 | $97M | +47.3% | $-110M | $-109M | -112.5% |
| Jun 2021 | $66M | +137.5% | $-59M | $-58M | -88.8% |
| Jun 2020 | $28M | +277.5% | $-21M | $-14M | -49.3% |
| Jun 2019 | $7M | — | $-17M | $-27M | -370.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2026 | $3M | $0M | $3M | — | — |
| Jun 2025 | $-2M | $0M | $-2M | — | — |
| Jun 2024 | $-1M | $0M | $-2M | — | — |
| Jun 2023 | $-5M | — | — | $-5.11 | — |
| Jun 2022 | $-29M | $0M | $-29M | $-74.01 | — |
| Jun 2021 | $-26M | $2M | $-28M | $-3.48 | — |
| Jun 2020 | $-28M | $0M | $-28M | $-3.01 | — |
| Jun 2019 | $-14M | $0M | $-14M | $-3.48 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $16M (+6.4% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 22, 2026DEF 14AProxy statement
- Sep 22, 202610-KAnnual report · period to Jun 2026
- Sep 22, 20268-KCurrent reportResults of operations
- Jun 25, 20268-KCurrent reportAgreement ended
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 2, 20268-KCurrent reportMaterial agreement · Results of operations · Unregistered share sale
- Feb 3, 202610-QQuarterly report · period to Dec 2025
- Feb 3, 20268-KCurrent reportResults of operations
- Jan 20, 20268-KCurrent reportRegulation FD disclosure
- Dec 10, 20258-KCurrent reportShareholder vote
- Nov 13, 202510-QQuarterly report · period to Sep 2025
Official filings of Aytu Bioscience with the US Securities and Exchange Commission.
Annual results
- Revenue
- $58 M
- Operating income
- $-8 M
- Net income
- $-14 M
For year ending June-2026 · source: SEC filing
Balance sheet
- Total assets
- $105 M
- Total liabilities
- $70 M
- Total equity
- $35 M
As of June-2026
Top 36 institutional investors in Aytu Bioscience#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 1,086,812 | -1,086,812 (-50.00%) | 10.00% | $2 M | Nov 13, 2026 |
| 2 | Stonepine Capital Management, LLC | 964,900 | +51,979 (+5.69%) | 8.88% | $2 M | Nov 13, 2026 |
| 3 | AWM Investment Company, Inc. | 619,574 | 0 (0.00%) | 5.70% | $1 M | Nov 13, 2026 |
| 4 | Vanguard Capital Management LLC | 261,146 | 0 (0.00%) | 2.40% | $1 M | Nov 13, 2026 |
| 5 | Crown Advisors Management, Inc. | 200,000 | 0 (0.00%) | 1.84% | $0 M | Nov 12, 2026 |
| 6 | Geode Capital Management, LLC | 123,670 | +30,023 (+32.06%) | 1.14% | $0 M | Nov 6, 2026 |
| 7 | Renaissance Technologies LLC | 121,623 | +16,800 (+16.03%) | 1.12% | $0 M | Nov 12, 2026 |
| 8 | Diadema Partners LP | 67,186 | -81,360 (-54.77%) | 0.62% | $0 M | Nov 16, 2026 |
| 9 | Two Sigma Investments, LP | 65,513 | -39,813 (-37.80%) | 0.60% | $0 M | Nov 16, 2026 |
| 10 | Dimensional Fund Advisors LP | 50,046 | +4,720 (+10.41%) | 0.46% | $0 M | Nov 4, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 48,144 | +1,096 (+2.33%) | 0.44% | $0 M | Nov 13, 2026 |
| 12 | Northern Trust Corp | 27,925 | 0 (0.00%) | 0.26% | $0 M | Nov 16, 2026 |
| 13 | BlackRock, Inc. | 22,793 | 0 (0.00%) | 0.21% | $0 M | Nov 13, 2026 |
| 14 | Persistent Asset Partners Ltd | 17,166 | -20,818 (-54.81%) | 0.16% | $0 M | Nov 13, 2026 |
| 15 | Citadel Advisors LLC | 12,678 | -36,736 (-74.34%) | 0.12% | $0 M | Nov 16, 2026 |
| 16 | Daytona Street Capital LLC | 10,000 | 0 (0.00%) | 0.09% | $0 M | Oct 15, 2026 |
| 17 | Acadian Asset Management LLC | 9,437 | -800 (-7.81%) | 0.09% | $0 M | Nov 9, 2026 |
| 18 | Nuveen, LLC | 2,101 | New | 0.02% | $0 M | Nov 10, 2026 |
| 19 | Tower Research Capital LLC (TRC) | 1,541 | -691 (-30.96%) | 0.01% | $0 M | Nov 16, 2026 |
| 20 | UBS Group AG | 895 | -1,482 (-62.35%) | 0.01% | $0 M | Nov 10, 2026 |
| 21 | Osaic Holdings, Inc. | 462 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 22 | Royal Bank Of Canada | 379 | +1 (+0.26%) | 0.00% | $0 M | Nov 16, 2026 |
| 23 | Jpmorgan Chase & Co | 188 | +34 (+22.08%) | 0.00% | $0 M | Nov 12, 2026 |
| 24 | Wells Fargo & Company/mn | 127 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 25 | Morgan Stanley | 125 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Show all 36: investors 26 to 36
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Group One Trading LLC | 37 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 27 | BNP Paribas Financial Markets | 23 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 28 | Citigroup Inc | 18 | New | 0.00% | $0 M | Nov 4, 2026 |
| 29 | Rockefeller Capital Management L.P. | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 30 | SBI Securities Co., Ltd. | 10 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 31 | NewEdge Advisors, LLC | 3 | New | 0.00% | $0 M | Nov 13, 2026 |
| 32 | Vision Financial Markets LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 33 | Arax Advisory Partners | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 34 | Caitong International Asset Management Co., Ltd | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 35 | Jones Financial Companies Lllp | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 36 | Tsfg, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
Mutual funds holding Aytu Bioscience#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 169,000 | $0 M | 1.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 92,146 | $0 M | 0.85% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 50,229 | $0 M | 0.46% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 11,929 | $0 M | 0.11% | <0.01% | +22% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 9,757 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 5,481 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 4,805 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 4,640 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 4,402 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 4,122 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 4,100 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 2,147 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 1,741 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 1,710 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 1,500 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 200 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 16 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Aytu Bioscience#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joshua R. DisbrowChief Executive Officer, Director | Grant or award | +30,000 | — | — | 237,203 | Form 4 |
| filed | Carl DockeryDirector | Grant or award | +10,000 | — | — | 31,152 | Form 4 |
| filed | John Donofrio Jr.Director | Grant or award | +10,000 | — | — | 23,762 | Form 4 |
| filed | Abhinav JainDirector | Grant or award | +10,000 | — | — | 29,500 | Form 4 |
| filed | Jarrett DisbrowChief Business Officer | Grant or award | +15,000 | — | — | 76,568 | Form 4 |
| filed | Greg PyszczymukaChief Commercial Officer | Grant or award | +20,000 | — | — | 56,102 | Form 4 |
| filed | Ryan J. SelhornChief Financial Officer | Grant or award | +25,000 | — | — | 74,743 | Form 4 |
| filed | Vivian H. LiuDirector | Grant or award | +10,000 | — | — | 29,825 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Aytu Bioscience#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split ; 12.174-for-1 split
Trading halts
- 2026-11-16 21:00 UTC, code T3, resumed 21:40 UTC
Fails to deliver
- : 29 shares at $1.91
- : 448 shares at $1.96
- : 41 shares at $2.01
- : 139 shares at $1.96
- : 105 shares at $1.99
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Aytu Bioscience scorecard#
Passes 9 of the 21 checks that could be worked out: strongest in valuation (3 of 5), weakest in growth (1 of 5). Fiscal year 2026; market cap of Oct 26, 2026.
Valuation3 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Biotechnology's median of 8.7×.
- ✓Free cash flow yield above 5%15.7%Free cash flow is 15.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 5
- ✗Revenue grew in the newest year-13.3%Revenue down 13.3% in fiscal 2026.
- ✗Revenue up more than 5% a year over three years-18.8%-18.8% a year over the three years to fiscal 2026.
- ✗Faster growth over three years than its peers' median-18.8%-18.8% a year against Biotechnology's median of 12.9% (181 companies).
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✓Net income higher than five years earlier-$14 M-$14 M in fiscal 2026 against -$58 M in 2021.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2026.
Profitability2 of 5
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2026.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
- ✓Operating margin above its peers' median-14.4%-14.4% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-52.5%-52.5% in fiscal 2026.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-14.4%-14.4% in fiscal 2026 against -15.9% in 2023.
Financial health3 of 6
- ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.13 at the end of fiscal 2026.
- ✓Debt below equity0.3×Debt to equity 0.26 at the end of fiscal 2026.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $17 M at the end of fiscal 2026.
- ✗Operating income covers interest five times-4.4×Operating income -4.4 times interest in fiscal 2026.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2026.
- ✗Altman Z-score outside the distress zone-4.09Z-score -4.09 (distress zone) for fiscal 2026.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2026#
Worked out from Aytu Bioscience's statements, beside the median of Biotechnology.
| Ratio | Trend | 2026 | Median of peers |
|---|---|---|---|
| Operating margin | -14.5% | -60.5% | |
| Net margin | -24.8% | -68.9% | |
| Return on equity | -52.5% | -61.0% | |
| Revenue growth, 3 years a year | -18.8% | 12.9% | |
| Revenue growth | -13.3% | 15.8% | |
| Debt to equity | 0.26× | 0.26× |
4of 9on the Piotroski tests of financial strength
- Revenue fell 13.3% against the year before.
- Net loss of $14 million, the 16th loss-making year in a row.
- Operating income covers the interest bill only -4.4 times.
- More cash than debt: net cash of $17 million.
Aytu Bioscience: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jun 30, 2026 | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 58−13.3%100% | 66+1.8%100% | 65r81−39.3%100% | 107+11.1%100% | 97+47.3%100% | 66+138%100% | 28+277%100% | 7.3+100%100% | 3.7+13.6%100% | 3.2—100% | |
| Cost of revenue | 21+1.0%36.0% | 21+27.4%31.0% | 16r26−60.4%24.7% | 41−8.2%38.0% | 44+21.8%45.9% | 36+340%55.5% | 8.3r7.6+276%30.0% | 2.2+7.4%30.1% | 2.1+44.7%56.0% | 1.4—44.0% | |
| Gross profit | 37−19.7%64.0% | 46−6.6%69.0% | 49r55−26.4%75.3% | 67+27.4%62.0% | 52+79.1%54.1% | 29+50.9%44.5% | 19—70.0% | — | — | — | |
| Research and development | 0−100%0.0% | 1.3−52.1%2.0% | 2.8r2.8−32.4%4.2% | 4.1−67.7%3.8% | 13r14+125%13.1% | 5.6+227%8.6% | 1.7r1.7+192%6.2% | 0.6+251%8.0% | 0.2−82.5%4.6% | 1.0—29.8% | |
| Selling, general and administrative | — | — | — | — | — | — | 35+84.3%126% | 19+6.5%258% | 18+1.7%484% | 17—541% | |
| Selling and marketing | 23+11.8%40.6% | 21−5.3%31.5% | 22r27−46.7%33.9% | 41+7.1%38.6% | 39+27.7%40.0% | 30+166%46.2% | 11—41.3% | — | — | — | |
| General and administrative | 19+10.9%33.5% | 17−12.9%26.2% | 20r23−30.3%30.6% | 29−8.1%26.7% | 31+22.2%32.2% | 26+29.7%38.9% | 20—71.1% | — | — | — | |
| Operating expenses | 45−15.9%78.4% | 54+5.9%80.8% | 51r60−39.5%77.7% | 84−48.4%77.9% | 162r164+84.2%168% | 88+118%134% | 40r49+67.5%147% | 24+3.5%330% | 23+0.1%638% | 23—725% | |
| Operating income | −8.3—−14.4% | −7.8—−11.8% | −1.6r−5.3—−2.4% | −17—−15.9% | −110r−112—−114% | −59—−89.7% | −21r−21—−76.5% | −17—−230% | −20—−538% | −20—−625% | |
| Interest expense and finance costs | 1.9−48.8%3.3% | 3.7−26.8%5.6% | 5.1r4.8+1.9%7.8% | 5.0+451%4.6% | 0.9—0.9% | — | 2.6+387%9.4% | 0.5−28.5%7.3% | 0.7−70.4%20.5% | 2.5—78.7% | |
| Other non-operating income (expense) | 0.7—1.2% | −0.5−159%−0.8% | 0.9r0.6+6114%1.3% | 0.0−98.6%0.0% | 1.0r1.3+21.1%1.1% | 0.8−88.8%1.3% | 7.5r7.5—27.2% | −10−208%−141% | 9.5—260% | −2.4—−74.0% | |
| Income before tax | −14—−24.7% | −14—−20.7% | −10r−14—−15.9% | −17—−15.9% | −109r−110—−113% | −58—−88.4% | −14—−49.3% | — | — | — | |
| Income tax | 0.0−95.2%0.0% | 0.4−79.6%0.7% | 2.1r1.8—3.3% | 0—0.0% | −0.1−142%−0.1% | 0.3—0.4% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | −14—−24.8% | −14—−21.4% | −13—−19.2% | — | — | — | — | — | — | — | |
| Income from discontinued operations | 0−100%0.0% | 0.6—0.9% | −3.3—−5.1% | — | — | — | — | — | — | — | |
| Net income including minority interests | — | — | — | −17—−15.9% | −109r−110—−113% | −58—−88.8% | −14—−49.3% | — | — | — | |
| Net income attributable to shareholders | −14—−24.8% | −14—−20.4% | −16—−24.3% | −17—−15.9% | −109r−110—−113% | −58—−88.8% | −14r−14—−49.3% | −27—−371% | −10—−278% | −23—−699% | |
| Earnings per share, basic | -1.16—— | -2.16—— | -2.86—— | -5.11—— | -74.01r-3.39—— | -3.48—— | -3.01r-0.30—— | -3.48—— | -15.31—— | -48.30—— | |
| Earnings per share, diluted | — | — | — | -5.11—— | -74.01r-3.75—— | -3.48—— | -3.01r-0.30—— | -3.48—— | -15.31—— | -48.30—— | |
| Shares, weighted average (basic) | 12+96.2%— | 6.3+13.4%— | 5.5+65.8%— | 3.3+127%— | 1.5r29−91.2%— | 17—— | — | — | — | — | |
| Shares, weighted average (diluted) | — | — | — | 3.3+127%— | 1.5r29−91.2%— | 17+271%— | 4.5r45−42.0%— | 7.8+1071%— | 0.7+42.8%— | 0.5—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 26−15.0%25.1% | 31+54.7%24.9% | 20−13.0%16.9% | 23+18.7%16.8% | 19−61.0%14.1% | 50+3.3%18.7% | 48r48+335%31.4% | 11+57.5%31.8% | 7.0+774%33.3% | 0.8—5.3% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Receivables | 23−26.9%21.7% | 31+32.4%25.1% | 24r24−18.7%19.9% | 29+33.3%21.2% | 22−22.9%15.8% | 28+400%10.6% | 5.6r5.2+224%3.7% | 1.7+201%5.0% | 0.6+9.6%2.7% | 0.5—3.5% | |
| Inventory | 6.9−40.0%6.5% | 11−5.8%9.2% | 12r13+1.2%10.3% | 12+10.6%8.8% | 11−33.6%7.9% | 16+63.4%6.2% | 10.0r10.0+594%6.5% | 1.4+7.6%4.1% | 1.3+2.0%6.4% | 1.3—8.7% | |
| Other current assets | 5.8+3.1%5.5% | 5.6−90.9%4.5% | 62−12.9%52.4% | 71r0.9+11129%52.1% | 0.6−39.0%0.5% | 1.0−81.9%0.4% | 5.7r5.7—3.7% | 0r1.0−100%0.0% | 0.4+41.6%2.1% | 0.3—2.1% | |
| Current assets | 62−22.0%58.8% | 79+27.9%63.8% | 62−15.0%52.4% | 73+21.5%53.4% | 60−43.1%43.5% | 105+39.5%39.6% | 75r75+389%49.2% | 15+63.0%44.4% | 9.5+213%45.0% | 3.0—20.2% | |
| Property, plant and equipment | 0.4−27.6%0.4% | 0.5−23.2%0.4% | 0.7−61.8%0.6% | 1.8−40.0%1.3% | 3.0−41.1%2.2% | 5.1+1888%1.9% | 0.3+26.9%0.2% | 0.2−6.8%0.6% | 0.2−66.2%1.0% | 0.6—4.3% | |
| Right-of-use (leased) assets | 0.9−19.2%0.8% | 1.1+28.0%0.9% | 0.8−59.6%0.7% | 2.1−37.2%1.5% | 3.3−8.2%2.4% | 3.6+462%1.3% | 0.6r0.6—0.4% | 0—0.0% | — | — | |
| Goodwill | — | — | — | 0—0.0% | 0−100%0.0% | 66+134%24.8% | 28r28—18.3% | 0—0.0% | — | 0.2—1.6% | |
| Other intangible assets | 41−1.9%39.4% | 42−19.5%34.0% | 52−11.1%44.4% | 59−16.5%43.2% | 71−17.4%51.3% | 85+74.9%32.2% | 49r490.0%31.9% | 49r0.2+19764%141% | 0.2−9.3%1.2% | 0.3—1.8% | |
| Non-current assets | 43−3.9%41.2% | 45−19.9%36.2% | 56−14.0%47.6% | 65r64−15.8%47.9% | 78−51.6%56.5% | 160+106%60.4% | 78r78+304%50.8% | 19+66.4%55.6% | 12−3.2%55.0% | 12—79.8% | |
| Total assets | 105−15.4%100% | 124+5.2%100% | 118−13.5%100% | 136−0.8%100% | 138−48.2%100% | 266+73.3%100% | 153r153+341%100% | 35+64.9%100% | 21+40.4%100% | 15—100% | |
| Accounts payable | 11+6.4%10.7% | 11+2.8%8.5% | 10r10−23.5%8.7% | 13—9.9% | — | 19+65.4%7.2% | 12r12+446%7.6% | 2.1r2.3+0.7%6.1% | 2.1−4.5%10.1% | 2.2—14.8% | |
| Debt due within a year | 1.90.0%1.8% | 1.90.0%1.5% | 1.9+2085%1.6% | 0.1−11.5%0.1% | 0.1−99.4%0.1% | 17+1597%6.3% | 1.0—0.6% | 0—0.0% | — | — | |
| Current liabilities | 55−13.3%52.1% | 63+1.3%50.8% | 62−9.8%52.7% | 69+7.1%50.6% | 64−41.1%46.8% | 109+280%41.2% | 29r28+435%18.8% | 5.4+58.3%15.5% | 3.4−6.0%16.1% | 3.6—24.1% | |
| Long-term debt | 9.1−16.5%8.7% | 11+0.2%8.8% | 11−26.1%9.2% | 15+3.0%10.8% | 14+7833%10.4% | 0.2—0.1% | 0—0.0% | — | — | — | |
| Lease liabilities (non-current) | 0.9−13.4%0.8% | 1.0+70.7%0.8% | 0.6−30.6%0.5% | 0.8−60.2%0.6% | 2.1−20.4%1.5% | 2.6+262%1.0% | 0.7r0.7—0.5% | 0—0.0% | — | — | |
| Non-current liabilities | 15−64.2%14.4% | 42+49.7%33.9% | 28+0.2%23.8% | 28—20.6% | — | — | — | — | — | — | |
| Total liabilities | — | — | — | 97+4.1%71.2% | 93r92−27.2%67.8% | 128+120%48.2% | 58r58+111%38.0% | 28+262%79.6% | 7.6−30.6%36.3% | 11—73.3% | |
| Retained earnings | −348—−331% | −334—−269% | −320—−271% | −304—−223% | −287r−288—−209% | −178—−67.1% | −120r−120—−78.3% | −106—−306% | −79—−376% | −69—−461% | |
| Shareholders' equity | 35+86.0%33.6% | 19−31.6%15.3% | 28−29.6%23.5% | 39−11.2%28.8% | 44r46−67.8%32.2% | 138+44.8%51.8% | 95r95+1241%62.0% | 7.1−47.2%20.4% | 13+236%63.7% | 4.0—26.7% | |
| Total equity | — | — | — | 39−11.2%28.8% | 44r46−67.8%32.2% | 138+44.8%51.8% | 95—62.0% | — | — | — | |
| Total liabilities and equity | 105−15.4%100% | 124+5.2%100% | 118−13.5%100% | 136−0.8%100% | 138−48.2%100% | 266+73.3%100% | 153r153+341%100% | 35+64.9%100% | 21+40.4%100% | 15—100% | |
| Shares outstanding | 11+19.5%— | 9.0+50.3%— | 6.0+8.3%— | 5.5+186%— | 1.9r39−93.0%— | 27+118%— | 13r126−28.2%— | 18+877%— | 1.8+4252%— | 0.0r0.8—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 3.9−26.9%6.8% | 5.4−35.0%8.1% | 8.3−6.2%12.7% | 8.8−13.1%8.2% | 10r10+10.3%10.5% | 9.2+61.0%14.0% | 5.7r6.2+110%20.7% | 2.7+5.2%37.3% | 2.6−40.6%70.8% | 4.4—135% | |
| Share-based compensation | 0.7+20.0%1.2% | 0.6−75.7%0.9% | 2.4r2.9−60.8%3.6% | 6.0+15.2%5.6% | 5.2+46.8%5.4% | 3.6+231%5.4% | 1.1r1.1+5.6%3.9% | 1.0+71.2%14.0% | 0.6r0.3−76.1%16.3% | 2.5—77.7% | |
| Cash from operating activities | 3.3—5.7% | −1.9—−2.9% | −1.4—−2.1% | −5.1—−4.8% | −29—−29.8% | −26—−39.6% | −28r−28—−103% | −14—−189% | −16—−436% | −14—−429% | |
| Capital expenditure | −0.0—−0.1% | −0.2—−0.3% | −0.3—−0.5% | — | 0—0.0% | −2.3—−3.6% | 0—0.0% | −0.1—−0.8% | −0.1—−2.0% | −0.1—−3.5% | |
| Intangible assets bought | 0—0.0% | −3.0—−4.5% | 0—0.0% | — | — | — | — | — | — | −6.0—−186% | |
| Cash from investing activities | −0.0—−0.1% | −2.6—−3.9% | −0.3—−0.5% | −0.1—−0.1% | −3.2—−3.4% | −2.8—−4.2% | −5.7r−5.7—−20.5% | −1.1—−14.5% | −0.5—−13.2% | −3.5—−110% | |
| Debt issued | 0−100%0.0% | 1.9−85.7%2.8% | 13—19.9% | — | — | — | 0.6—2.3% | 0r5.0—0.0% | 0—0.0% | — | |
| Debt repaid | −1.9—−3.2% | −1.9—−2.8% | −16—−24.1% | −0.1—−0.1% | — | — | — | — | — | — | |
| Shares issued | — | — | — | 16+33.2%14.5% | 12−74.0%12.1% | 45−31.5%68.6% | 66—238% | — | — | 0.7—23.0% | |
| Cash from financing activities | −7.9−151%−13.7% | 15—23.3% | −1.3−114%−1.9% | 8.9+480%8.3% | 1.5−95.0%1.6% | 30−57.3%46.2% | 71r71+273%257% | 19−15.8%261% | 23+122%619% | 10—316% | |
| Change in cash | −4.6−142%−8.1% | 11—16.5% | −3.0−182%−4.6% | 3.6—3.4% | −31−2048%−31.6% | 1.6−95.8%2.4% | 37r37+786%134% | 4.2−32.9%57.1% | 6.2—170% | −7.2—−223% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q4 FY2026to Jun 30, 2026 | Q3 FY2026to Mar 31, 2026 | Q2 FY2026to Dec 31, 2025 | Q1 FY2026to Sep 30, 2025 | Q4 FY2025to Jun 30, 2025 | Q3 FY2025to Mar 31, 2025 | Q2 FY2025to Dec 31, 2024 | Q1 FY2025to Sep 30, 2024 | Q4 FY2024to Jun 30, 2024 | Q3 FY2024to Mar 31, 2024 | Q2 FY2024to Dec 31, 2023 | Q1 FY2024to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 58−13.3%100% | 16*+6.4%100% | 12−32.7%100% | 15−6.5%100% | 14−16.2%100% | 15*+3.7%100% | 18+31.6%100% | 16−13.5%100% | 17−7.0%100% | 15r18*—100% | 14r18—100% | 19r23—100% | 18r22—100% | |
| Cost of revenue | 21+1.0%36.0% | 5.7*+16.7%35.4% | 4.8−14.8%38.8% | 5.5+2.0%36.5% | 4.7+2.5%33.9% | 4.9*+37.8%32.2% | 5.6+54.1%30.6% | 5.4+31.1%33.5% | 4.6−4.0%27.7% | 3.5r6.1*—24.3% | 3.7r6.3—26.1% | 4.1r6.7—22.1% | 4.8r7.3—26.8% | |
| Gross profit | 37−19.7%64.0% | 10*+1.5%64.6% | 7.6−40.7%61.2% | 9.6−10.8%63.5% | 9.2−23.4%66.1% | 10*−7.2%67.8% | 13+23.6%69.4% | 11−26.1%66.5% | 12−8.1%72.3% | 11r12*—75.7% | 10r12—73.9% | 15r16—77.9% | 13r15—73.2% | |
| Research and development | 0−100%0.0% | 0*−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.2*−79.3%1.4% | 0.2−73.5%0.9% | 0.5+0.2%3.2% | 0.4−28.4%2.6% | 1.0r1.0*—7.1% | 0.6r0.6—4.4% | 0.5r0.5—2.8% | 0.6r0.6—3.3% | |
| Selling and marketing | 23+11.8%40.6% | 6.1*+28.0%38.0% | 5.9+14.2%47.8% | 6.0+13.8%39.6% | 5.3−6.0%38.3% | 4.8*−11.8%31.6% | 5.2−3.0%28.1% | 5.3+1.0%32.5% | 5.7−7.1%34.1% | 5.4r6.4*—37.2% | 5.4r6.5—38.2% | 5.2r6.6—27.8% | 6.1r7.4—34.2% | |
| General and administrative | 19+10.9%33.5% | 4.3*+16.5%26.7% | 5.0+21.0%40.1% | 5.1+14.0%33.4% | 4.9−3.9%35.5% | 3.7*−8.2%24.4% | 4.1−14.9%22.3% | 4.4−7.3%27.4% | 5.1−18.6%30.9% | 4.0r4.7*—27.6% | 4.8r5.4—34.4% | 4.8r5.4—25.6% | 6.3r7.0—35.3% | |
| Operating expenses | 45−15.9%78.4% | 11*−37.4%69.5% | 12+12.3%94.0% | 12−7.1%76.5% | 11−17.2%77.0% | 18*+34.2%118% | 10−13.2%56.3% | 12+8.9%76.9% | 13−7.1%77.9% | 13r16*—91.3% | 12r14—85.3% | 11r14—61.1% | 14r16—78.0% | |
| Operating income | −8.3—−14.4% | −0.8*—−4.8% | −4.1−268%−32.7% | −2.0—−13.0% | −1.5—−10.8% | −7.6*—−50.4% | 2.4—13.1% | −1.7−154%−10.4% | −0.9—−5.6% | −2.3r−3.7*—−15.6% | −1.6r−2.5—−11.4% | 3.1r2.4—16.8% | −0.9r−1.5—−4.9% | |
| Interest expense and finance costs | 1.9−48.8%3.3% | 0.4*−47.5%2.4% | 0.4−51.6%3.5% | 0.6−48.1%3.7% | 0.5−48.1%3.7% | 0.7*−41.7%4.8% | 0.9−28.4%4.9% | 1.1−14.8%6.7% | 1.0−22.5%6.0% | 1.3r1.0*—8.6% | 1.3—9.0% | 1.3—6.8% | 1.3—7.2% | |
| Other non-operating income (expense) | 0.7—1.2% | 0.2*—1.1% | 0.1+314%1.2% | 0.2+35.7%1.3% | 0.2−62.9%1.4% | −1.2*−1125%−8.1% | 0.0−48.6%0.2% | 0.1+45.8%0.9% | 0.5—3.3% | 0.1r3.7*—0.8% | 0.1r−1.2—0.5% | 0.1r−1.2—0.5% | −6.6—−37.1% | |
| Income before tax | −14—−24.7% | −0.0*—−0.0% | −5.6−247%−45.2% | −11−2871%−69.8% | 2.0+31.2%14.1% | −19*—−128% | 3.8—20.7% | 0.4−72.7%2.4% | 1.5—9.0% | −2.5r−3.9*—−17.4% | −1.8r−2.6—−12.6% | 1.4r0.6—7.5% | −7.5r−8.1—−41.9% | |
| Income tax | 0.0−95.2%0.0% | 0.0*−97.5%0.1% | 0.0—0.1% | 0—0.0% | 0−100%0.0% | 0.4*−48.0%2.9% | −0.1−123%−0.7% | −0.3−136%−1.7% | 0.4—2.4% | 0.8r0.7*—5.8% | 0.5r0.2—3.7% | 0.8r0.8—4.2% | 0—0.0% | |
| Income from continuing operations | −14—−24.8% | −0.0*—−0.1% | −5.6−243%−45.3% | −11−1692%−69.8% | 2.0+79.8%14.1% | −20*—−131% | 3.9—21.4% | 0.7+7.4%4.1% | 1.1—6.6% | −3.4*—−23.1% | −2.3—−16.3% | 0.6—3.3% | −7.5—−41.9% | |
| Income from discontinued operations | 0−100%0.0% | 0*−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.1*—0.4% | 0.1—0.3% | 0.1—0.8% | 0.4—2.3% | −1.2*—−8.5% | −0.6—−4.3% | −0.8—−4.5% | −0.6—−3.6% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | — | — | — | −8.1—−45.6% | |
| Net income attributable to shareholders | −14—−24.8% | −0.0*—−0.1% | −5.6−241%−45.3% | −11−1443%−69.8% | 2.0+33.3%14.1% | −20*—−131% | 4.0—21.6% | 0.8—4.9% | 1.5—8.9% | −4.6*—−31.6% | −2.9—−20.6% | −0.2—−1.2% | −8.1—−45.6% | |
| Earnings per share, basic | — | — | -0.53−182%— | -1.05−908%— | 0.21−12.5%— | — | 0.65—— | 0.13—— | 0.24—— | — | -0.52—— | -0.04—— | -1.48—— | |
| Earnings per share, diluted | — | — | -0.53−352%— | -1.05—— | -0.08—— | — | 0.21—— | -0.26—— | -0.15—— | — | -0.52—— | -0.04—— | -1.48—— | |
| Shares, weighted average (basic) | — | — | 11+71.3%— | 10+63.7%— | 9.4+55.6%— | — | 6.1+10.9%— | 6.1+11.1%— | 6.1+10.7%— | — | 5.5—— | 5.5—— | 5.5—— | |
| Shares, weighted average (diluted) | — | — | 11+28.1%— | 10+18.3%— | 19+114%— | — | 8.2+48.3%— | 8.5+53.8%— | 9.1+66.0%— | — | 5.5—— | 5.5—— | 5.5—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 26—25.1% | 26−15.0%25.1% | 27+47.0%23.9% | 30+47.2%24.6% | 33+62.3%26.1% | 31+54.7%24.9% | 18−8.0%14.6% | 20+4.4%17.6% | 20+0.7%17.4% | 20—16.9% | 20—15.3% | 20—14.9% | 20—15.0% | |
| Receivables | 23—21.7% | 23−26.9%21.7% | 24−31.6%21.9% | 31+21.7%25.3% | 33+43.5%26.6% | 31+32.4%25.1% | 36+19.7%28.8% | 25−13.6%21.9% | 23−22.5%20.0% | 24r24—19.9% | 30—23.2% | 29—22.4% | 30—22.5% | |
| Inventory | 6.9—6.5% | 6.9−40.0%6.5% | 7.5−32.5%6.7% | 8.7−21.9%7.1% | 10−14.0%8.1% | 11−5.8%9.2% | 11−16.2%8.9% | 11−14.7%9.5% | 12−9.5%10.1% | 12r13—10.3% | 13—10.2% | 13—9.9% | 13—9.8% | |
| Other current assets | 5.8—5.5% | 5.8+3.1%5.5% | 8.7+16.2%7.8% | 6.6−89.5%5.4% | 5.2−91.5%4.1% | 5.6−90.9%4.5% | 7.5+643%6.0% | 63+4630%54.2% | 61+8009%52.4% | 62—52.4% | 1.0—0.8% | 1.3—1.0% | 0.7—0.6% | |
| Current assets | 62—58.8% | 62−22.0%58.8% | 67−7.2%60.3% | 76—62.5% | 81—64.9% | 79+27.9%63.8% | 73+1.9%58.4% | — | — | 62—52.4% | 71—55.2% | 71—54.4% | 71—53.1% | |
| Property, plant and equipment | 0.4—0.4% | 0.4−27.6%0.4% | 0.4−25.5%0.4% | 0.5−6.2%0.4% | 0.5−27.7%0.4% | 0.5−23.2%0.4% | 0.5−43.5%0.4% | 0.5−54.2%0.4% | 0.7−59.8%0.6% | 0.7—0.6% | 1.0—0.8% | 1.1—0.9% | 1.7—1.3% | |
| Right-of-use (leased) assets | 0.9—0.8% | 0.9−19.2%0.8% | 0.9−18.1%0.8% | 1.0−18.6%0.8% | 1.0−17.6%0.8% | 1.1+28.0%0.9% | 1.1−38.1%0.9% | 1.2−44.8%1.0% | 1.2−50.1%1.1% | 0.8—0.7% | 1.8—1.4% | 2.1—1.6% | 2.5—1.8% | |
| Other intangible assets | 41—39.4% | 41−1.9%39.4% | 42−12.8%38.0% | 44−12.8%35.7% | 41−19.1%33.1% | 42−19.5%34.0% | 49−9.9%39.2% | 50−10.3%43.0% | 51−10.7%44.2% | 52—44.4% | 54—42.0% | 56—42.4% | 57—43.1% | |
| Non-current assets | 43—41.2% | 43−3.9%41.2% | 44−14.2%39.7% | 46−13.9%37.5% | 44−20.4%35.1% | 45−19.9%36.2% | 52−10.5%41.6% | 53−11.2%45.8% | 55−11.6%47.6% | 56—47.6% | 58—44.8% | 60—45.6% | 62—46.9% | |
| Total assets | 105—100% | 105−15.4%100% | 112−10.1%100% | 122+5.0%100% | 125+7.9%100% | 124+5.2%100% | 124−3.6%100% | 116−11.4%100% | 116−12.8%100% | 118—100% | 129—100% | 131—100% | 133—100% | |
| Accounts payable | 11—10.7% | 11+6.4%10.7% | 13+9.7%11.8% | 14+21.9%11.7% | 12−8.7%9.9% | 11+2.8%8.5% | 12+14.9%9.7% | 12+11.7%10.1% | 14—11.7% | 10r10—8.7% | 10—8.1% | 10—8.0% | — | |
| Debt due within a year | 1.9—1.8% | 1.90.0%1.8% | 1.90.0%1.7% | 1.90.0%1.5% | 1.90.0%1.5% | 1.90.0%1.5% | 1.9−87.7%1.5% | 1.9+4662%1.6% | 1.9+2895%1.6% | 1.9—1.6% | 15—11.7% | 0.0—0.0% | 0.1—0.0% | |
| Current liabilities | 55—52.1% | 55−13.3%52.1% | 60−15.2%53.7% | 66+2.4%53.7% | 66+7.7%52.8% | 63+1.3%50.8% | 71−15.5%56.9% | 64−0.2%55.1% | 61−6.4%52.9% | 62—52.7% | 84—64.9% | 64—48.9% | 65—49.3% | |
| Long-term debt | 9.1—8.7% | 9.1−16.5%8.7% | 9.5+0.1%8.5% | 10.0+0.2%8.2% | 10+0.2%8.4% | 11+0.2%8.8% | 9.5—7.7% | 10.0−33.3%8.6% | 10−29.7%9.0% | 11—9.2% | 0—0.0% | 15—11.4% | 15—11.2% | |
| Lease liabilities (non-current) | 0.9—0.8% | 0.9−13.4%0.8% | 0.9−8.2%0.8% | 1.0−12.0%0.8% | 1.0−10.6%0.8% | 1.0+70.7%0.8% | 1.0+27.8%0.8% | 1.1—1.0% | 1.1−5.3%1.0% | 0.6—0.5% | 0.8—0.6% | — | 1.2—0.9% | |
| Non-current liabilities | 15—14.4% | 15−64.2%14.4% | 17−10.9%14.8% | 42+97.2%34.6% | 36+44.7%28.7% | 42+49.7%33.9% | 19+29.2%15.0% | 21−37.4%18.4% | 25—21.4% | 28—23.8% | 14—11.2% | 34—26.1% | — | |
| Total liabilities | — | — | — | — | — | — | — | — | — | — | — | — | 101—75.8% | |
| Retained earnings | −348—−331% | −348—−331% | −348—−311% | −342—−280% | −332—−265% | −334—−269% | −314—−253% | −318—−273% | −318—−275% | −320—−271% | −315—−245% | −312—−238% | −312—−235% | |
| Shareholders' equity | 35—33.6% | 35+86.0%33.6% | 35+0.7%31.5% | 14−53.8%11.6% | 23−22.3%18.5% | 19−31.6%15.3% | 35+13.4%28.1% | 31−6.4%26.5% | 30−7.3%25.7% | 28—23.5% | 31—23.9% | 33—25.0% | 32—24.2% | |
| Total equity | — | — | — | — | — | — | — | — | — | — | — | — | 32—24.2% | |
| Total liabilities and equity | 105—100% | 105−15.4%100% | 112−10.1%100% | 122+5.0%100% | 125+7.9%100% | 124+5.2%100% | 124−3.6%100% | 116−11.4%100% | 116−12.8%100% | 118—100% | 129—100% | 131—100% | 133—100% | |
| Shares outstanding | 11—— | 11+19.5%— | 11+74.0%— | 11+74.0%— | 9.9+61.2%— | 9.0+50.3%— | 6.2+10.8%— | 6.2+10.8%— | 6.1+11.2%— | 6.0—— | 5.6—— | 5.6—— | 5.5—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 3.9−26.9%6.8% | 1.1*−23.4%7.0% | 1.1*−12.9%9.0% | 0.9*−31.5%5.8% | 0.8−39.8%5.8% | 1.5r1.3*−24.7%9.7% | 1.3r1.5*−29.8%7.0% | 1.3*−32.0%8.0% | 1.3−40.2%8.0% | 1.9*—13.3% | 1.8—13.1% | 1.9—10.1% | 2.2—12.5% | |
| Share-based compensation | 0.7+20.0%1.2% | 0.1*+29.2%0.9% | 0.1+6.5%1.2% | 0.3+87.4%1.9% | 0.1−34.1%0.8% | 0.1*−53.3%0.7% | 0.1−82.9%0.8% | 0.2−81.6%0.9% | 0.2−81.4%1.0% | 0.2r0.4*—1.7% | 0.8—5.8% | 0.8—4.4% | 0.9—5.2% | |
| Cash from operating activities | 3.3—5.7% | 4.4*+57.2%27.4% | −4.2*—−33.7% | 3.7*+26.5%24.2% | −0.6—−4.4% | 2.8*—18.5% | −6.5*—−35.0% | 2.9*—17.9% | −1.2—−7.2% | −0.8*—−5.4% | −0.3*—−1.8% | −0.1*—−0.7% | −0.2—−1.2% | |
| Capital expenditure | −0.0—−0.1% | −0.0*—−0.1% | 0*—0.0% | −0.0*—−0.1% | 0—0.0% | −0.0*—−0.1% | −0.1*—−0.4% | −0.0*—−0.0% | −0.1—−0.8% | — | 0*—0.0% | — | — | |
| Cash from investing activities | −0.0—−0.1% | −0.0*—−0.1% | 0*—0.0% | −0.0*−112%−0.1% | 0−100%0.0% | −3.0*—−19.9% | −0.1*—−0.4% | 0.1*—0.9% | 0.4—2.3% | −0.0*—−0.2% | −0.0*—−0.3% | −0.2*—−0.9% | −0.1—−0.4% | |
| Debt repaid | −1.9—−3.2% | −0.5*—−2.9% | −0.5*—−3.7% | −0.5*—−3.1% | −0.5—−3.3% | −0.5*—−3.1% | −0.5*—−2.5% | −0.5*—−2.9% | −0.5—−2.8% | −16*—−107% | −0.0*—−0.2% | — | — | |
| Cash from financing activities | −7.9−151%−13.7% | −4.8*−137%−29.8% | 0.9*−79.7%7.0% | −6.3*—−41.3% | 2.3+152%16.5% | 13*+1117%85.8% | 4.3*+711%23.3% | −2.8*—−17.0% | 0.9—5.5% | 1.1*—7.3% | 0.5*—3.8% | −0.1*—−0.7% | −2.7—−15.3% | |
| Change in cash | −4.6−142%−8.1% | −0.4*−103%−2.5% | −3.3*—−26.7% | −2.6*−998%−17.2% | 1.7+1545%12.1% | 13*+5095%84.4% | −2.2*−1063%−12.1% | 0.3*—1.8% | 0.1—0.6% | 0.2*—1.7% | 0.2*—1.6% | −0.4*—−2.3% | −3.0—−17.0% | |
| Report | Worked out | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Aytu Bioscience sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- ADHD Portfolio$46 M80%-20%
- E X X U A Portfolio$7 M11%—
- The Pediatric Portfolio$5 M8.9%-41%
- Product and Service, Other$0 M0.1%+0.0%
Business segments
- RX$58 M100%-13%
Source: SEC annual report (XBRL data) · as of Jun 30, 2026
Executive pay at Aytu Bioscience#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Joshua R. Disbrow | $845 K | $855 K | $553 K | $134 |
| 2025Joshua R. Disbrow | $884 K | $867 K | $462 K | $136 |
| 2024Joshua R. Disbrow | $928 K | $919 K | $548 K | $183 |
Source: SEC proxy statement (Form DEF 14A) · as of Jun 30, 2026
Events at Aytu Bioscience#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 5 · Agreement ended 2 · New debt 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleShareholder rights changedResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Agreement ended | 8-K | |
| Material agreementNew debt | 8-K | |
| Acquisition or sale completedMaterial agreement | 8-K | |
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementNew debt | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 22, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2019 | $10 M | Private placement after listing | $10 to $50 million | 2 | equity, options | SEC |
| Aug 2017 | $12 M | Private placement after listing | $10 to $50 million | 70 | equity, options | SEC |
| May 2017 | $2 M | Private placement after listing | Under $2 million | 16 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Aytu Bioscience#
$0 spent on lobbying the US Congress and federal agencies in 2025.
Lobbying firms hired in 2025
Dorsey & Whitney LLP
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $0 | — | 3 |
| 2025 | $0 | — | 4 |
| 2024 | $10 K | — | 4 |
| 2023 | $20 K | — | 5 |
| 2022 | $0 | — | 3 |
| 2021 | $30 K | — | 4 |
| 2020 | $40 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Aytu BioPharma, Inc. (formerly known as Aytu BioScience, Inc.)” and “Aytu BioScience, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Aytu Bioscience#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $100 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Commercial Reporting and Analytics ManagerData Scientists | 1 | $100 K |
Where: Denver, CO 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2024 | 1 | 1 | $100 K | 1 |
| FY2021 | 1 | 1 | $68 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aytu BioPharma, Inc.
How Aytu Bioscience compares in Biotechnology
- Market cap$21 M · higher than 18% of 726
- Revenue$58 M · higher than 61% of 647
- Net margin-24.8% · higher than 58% of 408
- Revenue growth-13.3% · higher than 32% of 438
- Price / sales0.4× · lower than 98% of 339
- Price / book0.6× · lower than 90% of 534
- FCF yield15.7% · higher than 99% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Aytu Bioscience🇺🇸 | $21 M | — | -24.8% | -13.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending June-2026
- Balance sheet:
- As of June-2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Aytu Bioscience? Verify and update this profile — free
Show Aytu Bioscience's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.